Bhamidipati D - Search Results

1

PARP inhibitors: enhancing efficacy through rational combinations.

Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. Bhamidipati D, et al. Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10. Br J Cancer. 2023. PMID: 37430137 Free PMC article. Review.

2

Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.

Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Fox DA, et al. Among authors: bhamidipati d. Eur J Cancer. 2023 Nov;194:113356. doi: 10.1016/j.ejca.2023.113356. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37827065

3

Pleural Marginal Zone Lymphoma Masquerading as Metastatic Adenocarcinoma of the Lung.

Onatsko N, Karam I, Thida A, Attia H, Bhamidipati D, Hamadi R, Gupta R, Preet M. Onatsko N, et al. Among authors: bhamidipati d. Cureus. 2024 Nov 11;16(11):e73462. doi: 10.7759/cureus.73462. eCollection 2024 Nov. Cureus. 2024. PMID: 39664121 Free PMC article.

4

Trends in Enforcement of National Comprehensive Cancer Network Financial Conflict of Interest Policy.

Saririan N, Bhamidipati D, Dey P, Persaud S, Chakraborty N, Tabatabai S, Gallagher G, Trivedi NU, Mitchell AP. Saririan N, et al. Among authors: bhamidipati d. JNCI Cancer Spectr. 2024 Nov 26:pkae120. doi: 10.1093/jncics/pkae120. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 39589914

5

Emerging Tumor-Agnostic Molecular Targets.

Bhamidipati D, Schram AM. Bhamidipati D, et al. Mol Cancer Ther. 2024 Nov 4;23(11):1544-1554. doi: 10.1158/1535-7163.MCT-23-0725. Mol Cancer Ther. 2024. PMID: 39279103 Review.

6

Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.

Pellatt AJ, Bhamidipati D, Subbiah V. Pellatt AJ, et al. Among authors: bhamidipati d. JCO Oncol Pract. 2024 Oct;20(10):1289-1292. doi: 10.1200/OP.24.00295. Epub 2024 May 13. JCO Oncol Pract. 2024. PMID: 38739884 Review.

7

Targeting All BRAF Alterations: The (Re)-Search Continues.

Bhamidipati D, Pellatt A, Subbiah V. Bhamidipati D, et al. JCO Precis Oncol. 2024 Feb;8:e2300670. doi: 10.1200/PO.23.00670. JCO Precis Oncol. 2024. PMID: 38380848

8

Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer.

Bhamidipati D, Yedururi S, Huse J, Chinapuvvula SV, Wu J, Subbiah V. Bhamidipati D, et al. JCO Precis Oncol. 2023 Sep;7:e2300252. doi: 10.1200/PO.23.00252. JCO Precis Oncol. 2023. PMID: 38039431 No abstract available.

9

Tumor-agnostic drug development in dMMR/MSI-H solid tumors.

Bhamidipati D, Subbiah V. Bhamidipati D, et al. Trends Cancer. 2023 Oct;9(10):828-839. doi: 10.1016/j.trecan.2023.07.002. Epub 2023 Jul 28. Trends Cancer. 2023. PMID: 37517955 Review.

10

Cracking KRAS^G12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine.

Bhamidipati D, Subbiah V. Bhamidipati D, et al. ESMO Open. 2023 Aug;8(4):101591. doi: 10.1016/j.esmoop.2023.101591. Epub 2023 Jun 30. ESMO Open. 2023. PMID: 37393631 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters